AC Health Invests in Predictive Healthcare Technology Company, Fibronostics

Ayala Healthcare Holdings, Inc. (AC Health), through its technology arm, Vigos, expanded its digital portfolio with a recent investment in Fibronostics, a global US-based healthcare technology company focusing on non-invasive algorithm-based solutions for diagnostic testing.

The agreement was signed by AC Health President and CEO, Paolo Borromeo, AC Health Chief Digital Officer, Christian Besler, and SPRIM Ventures Managing Partner, Dr. Michael Shleifer last May 31, 2019. SPRIM is the bioscience R&D firm from which Fibronostics was spun off.

Founded in 2015, Fibronostics aims to improve screening, follow-up, and diagnosis through non-invasive products. Key focus areas include prevalent chronic conditions such as liver disease, coronary heart disease, stroke, diabetes, and obstructive sleep apnea.

“This investment fits well into our Vigos health technology portfolio, which we are proud to say is the first digital health portfolio in the Philippines. We are always on the lookout for technology solutions that empower our doctors and improve quality for our patients,” said Borromeo.

As part of the partnership, AC Health will launch two Fibronostics products, LiverFAST and HealthFACTR, in its FamilyDOC clinics. LiverFAST is a proprietary algorithm that analyzes 10 biomarkers from a blood sample to help screen and monitor common liver diseases. The test is intended to be a simple and less expensive option to other diagnostics, such as liver biopsy or liver imaging. HealthFACTR, on the other hand, is as a 10-minute metabolic health check-up solution that provides immediate risk assessment and personalized recommendations, based on the latest medical guidelines.

“We believe LiverFAST and HealthFACTR can help make diagnostic tests more meaningful for patients and doctors. These algorithms are excellent examples of how we can harness healthcare data and analytics to improve clinical decision-making,” Besler added.

Meanwhile, Dr. Shleifer believes that the partnership would encourage more patients to appreciate the value of screening and preventive health.

“We are very excited to collaborate with AC Health. Through their network of FamilyDOC clinics, we hope to reach many more patients in the Philippines, where the burden of chronic diseases has been growing. Ultimately, our goal is to screen patients early so that they can work in partnership with their doctors to maintain good health and prevent complications,” shared Dr. Shleifer.

Vigos also has investments in MedGrocer (a technology-enabled medicine-as-a-service for companies and drug manufacturers), AIDE (a home healthcare mobile platform), and Tikehau-SPRIM (a Singaporebased health fund). It has also built its own suite of health technology products including VigosEMR, an Electronic Medical Records and Clinic Information System, which is being used across all FamilyDOC clinics, and Vigos CARE, an integrated corporate health solutions platform allowing companies and employees to maximize their health benefits.

AC Health

Ayala Healthcare Holdings, Inc. (AC Health) is a wholly-owned subsidiary of the Ayala Corporation, and serves as the portfolio company for healthcare businesses. Its vision is to build an ecosystem that links every patient to a seamless healthcare experience. Its portfolio includes Generika Drugstore, the pioneer in generic retail pharmacies, and FamilyDOC, a new chain of community-based primary care clinics. AC Health is also investing in health technology solutions, such as its HealthTech arm, Vigos Health Technologies, MedGrocer, a technology-enabled medicine-as-a-service for companies and drug manufacturers, and AIDE, a home health care platform.


Fibronostics is a TKS-1 portfolio company developing non-invasive algorithm-based diagnostics and patient screening solutions to facilitate identification, diagnostic and improve treatment outcomes in various chronic conditions including liver, kidney and metabolic disorders.

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.